Evidence-based therapy of polycystic ovarian syndrome
Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women. The heterogeneous endocrinopathy is characterized by clinical and/or biochemical hyperandrogenism, oligo- or amenorrhoea, anovulatory infertility, and polycystic ovarian morphology. The syndrome is often associated with obesity, hyperinsulinemia and adversely affects endocrine, metabolic, and cardiovascular health. The symptoms and complaint of the patients vary with age. To maximise health gain of the syndrome, adequate, evidence based effective, efficient and safe treatment is necessary. This article summarises the highest available evidence provided by studies, meta-analysis and systematic reviews about the therapeutical possibilities for treating obesity, hyperandrogenism, menstrual abnormalities, infertility and psychological problems related to polycystic ovary syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 156(2015), 45 vom: 08. Nov., Seite 1803-15 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A polycystás ovarium szindróma tüneteinek bizonyítékokon alapuló terápiája |
|---|
| Beteiligte Personen: |
Gődény, Sándor [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.03.2016 Date Revised 10.11.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2015.30253 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM254472419 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM254472419 | ||
| 003 | DE-627 | ||
| 005 | 20231224172439.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2015.30253 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0848.xml |
| 035 | |a (DE-627)NLM254472419 | ||
| 035 | |a (NLM)26551444 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Gődény, Sándor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evidence-based therapy of polycystic ovarian syndrome |
| 246 | 3 | 3 | |a A polycystás ovarium szindróma tüneteinek bizonyítékokon alapuló terápiája |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2016 | ||
| 500 | |a Date Revised 10.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women. The heterogeneous endocrinopathy is characterized by clinical and/or biochemical hyperandrogenism, oligo- or amenorrhoea, anovulatory infertility, and polycystic ovarian morphology. The syndrome is often associated with obesity, hyperinsulinemia and adversely affects endocrine, metabolic, and cardiovascular health. The symptoms and complaint of the patients vary with age. To maximise health gain of the syndrome, adequate, evidence based effective, efficient and safe treatment is necessary. This article summarises the highest available evidence provided by studies, meta-analysis and systematic reviews about the therapeutical possibilities for treating obesity, hyperandrogenism, menstrual abnormalities, infertility and psychological problems related to polycystic ovary syndrome | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a EBM | |
| 650 | 4 | |a PCOS | |
| 650 | 4 | |a clinical features | |
| 650 | 4 | |a klinikai tünetek | |
| 650 | 4 | |a terápia | |
| 650 | 4 | |a therapy | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Anti-Obesity Agents |2 NLM | |
| 650 | 7 | |a Chorionic Gonadotropin |2 NLM | |
| 650 | 7 | |a Contraceptives, Oral, Hormonal |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 700 | 1 | |a Csenteri, Orsolya Karola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 156(2015), 45 vom: 08. Nov., Seite 1803-15 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2015 |g number:45 |g day:08 |g month:11 |g pages:1803-15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2015.30253 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2015 |e 45 |b 08 |c 11 |h 1803-15 | ||